Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Diseases 1Blast Crisis 1

Interventions

Cyclophosphamide 5nilotinib 4Cytarabine 4fludarabine 3Methotrexate 3Imatinib Mesylate 3Dasatinib 3Busulfan 3fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2AP 1903 reagent 2sargramostim 1ruxolitinib 1merphos 1amsonic acid 1Whole-Body Irradiation 1Vincristine 1Valproic Acid 1Thiotepa 1Tacrolimus 1Sirolimus 1Saline Solution 1Rituximab 1Prednisone 1Ondansetron 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Cladribine × Clear all
NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

University of Cincinnati

Phase 2 Withdrawn
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡